Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial-Reference-Cited by-同舟云学术

Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial

Published:2024-08 Issue: Volume:274 Page:119-129
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Arrigo Mattia,Davison Beth,Edwards Christopher,Adamo Marianna,Ambrosy Andrew P.,Barros Marianela,Biegus Jan,Celutkiene Jelena,Čerlinskaitė-Bajorė Kamilė,Chioncel Ovidiu,Cohen-Solal Alain,Damasceno Albertino,Diaz Rafael,Filippatos Gerasimos,Gayat Etienne,Kimmoun Antoine,Lam Carolyn S.P.,Metra Marco,Novosadova Maria,Pagnesi Matteo,Pang Peter S.,Ponikowski Piotr,Saidu Hadiza,Sliwa Karen,Takagi Koji,Ter Maaten Jozine M.,Tomasoni Daniela,Voors Adriaan A.,Cotter Gad,Mebazaa Alexandre

Publisher

Elsevier BV

Reference5 articles.

1. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study;Kimmoun;Eur J Heart Fail,2019

2. Amended STRONG-HF study design;Cotter;Eur J Heart Fail,2021

3. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial;Mebazaa;Lancet,2022

4. Differences between patients enrolled early and late during clinical trial recruitment: insights from the HF-ACTION trial;Warraich;Circ Cardiovasc Qual Outcomes,2018

5. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of vasopressin antagonism in heart failure: outcome study with Tolvaptan) trial;Butler;J Am Coll Cardiol,2013